LARIMAR THERAPEUTICS INC (LRMR) Stock Price, Quote, News and Overview

Company Profile

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company is headquartered in Bala Cynwyd, Pennsylvania and currently employs 42 full-time employees. The company went IPO on 2014-06-19. The firm is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.

Company Info

LARIMAR THERAPEUTICS INC

Three Bala Plaza East. Suite 506

Bala Cynwyd PENNSYLVANIA 19004 US

CEO: Carole Ben-Maimon

Employees: 42

Company Website: https://larimartx.com/

Investor Relations: https://investors.larimartx.com/

Phone: 18445119056